Popular Analysis

Anthem Biosciences IPO GMP

Anthem Biosciences IPO GMP grey market premium, review, Subscription, allotment, listing estimate @ Chanakyanipothi.com
+A legacy of 31 Years.
+India`s Oldest Investment & IPO website.
+Most Trusted by Investors across India.

Table of Contents

Listing review of Anthem Biosciences IPO 

The IPO is listed on 21 July 2025 @ Rs. 723.05. The listing is marginally below the expectations of the grey market, which anticipated the listing to be at Rs. 743.

Subscription Status

QIB B HNI X S HNI X NII X RII X Total X
192.80 51.66 30.80 44.70 5.98 67.42
Applications: 37,94,038
Subscription Review:
Pace of application has been excellent on the last day

 

Who is the promoter of Anthem Biosciences IPO?   

The promoters of the company are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj and they hold 77.23% of the pre-IPO capital of the company.

What are the Objects of Anthem Biosciences IPO?

The Company will not receive any proceeds from the Offer (the “Offer Proceeds”) and all the Offer Proceeds will be received by the Selling Shareholders after deduction of Offer related expenses and relevant taxes thereon, to be borne by the respective Selling Shareholders.

What is the business of Anthem Biosciences?

About Anthem Biosciences Limited
Innovating Molecule to Market Since 2006

Founded in 2006, Anthem Biosciences Limited is a cutting-edge, innovation-led Contract Research, Development & Manufacturing Organization (CRDMO). With fully integrated operations spanning drug discovery, development, and commercial manufacturing, it partners with some of the world’s most forward-thinking biotech startups and global pharmaceutical leaders.

Its specialty lies in fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars—serving high-impact healthcare markets around the world.

Global Reach. Scientific Depth.

  • 44+ countries served, including the U.S., Europe, and Japan

  • 550+ customers across CRDMO and specialty ingredients businesses

  • Trusted by both emerging biotech innovators and top-tier pharmaceutical giants

Pipeline Highlights (as of September 30, 2024):

  • 196 active R&D and manufacturing projects

    • 170 discovery projects (284 molecules synthesized)

    • 132 early-phase & 16 late-phase development programs

    • 13 commercial manufacturing projects (covering 10 molecules)

  • APIs and intermediates manufactured for 10 commercial molecules, all supported from the discovery stage

Intellectual Property & Innovation

  • 8 granted patents (1 in India, 7 overseas)

  • 24 pending global applications, including key process patents in glycolipid synthesis and GLP-1 analogues

Powered by People

Its team of over 600 skilled professionals includes:

  • Medicinal chemists

  • Microbiologists & molecular biologists

  • Biochemists & chemical engineers

  • In-vivo non-clinical research specialists


Anthem Biosciences is not just a service provider—it is a scientific partner committed to transforming molecules into medicines that impact lives across the globe.

Anthem Biosciences IPO GMP grey market premium, review, Subscription, allotment, listing estimate

Anthem Biosciences IPO Details 

IPO opens on  14 July 2025
IPO closes on  16 July 2025
Issue Type Book Built Issue IPO
Issue Size 59575250 Shares /
Rs 3395 Crore
* Fresh Issue ? Shares /
Rs  Crore
* Offer for Sale  59575250 shares/
Rs.3395 Crore
   
Face Value per share: Rs. 2
Price Band  Rs.540-570
Retail Discount  Rs 0 per share
Employee discount  Rs. 50 per share
Retail Lot Size   26Shares
Listing will at  BSE, NSE

Shares offered in
Anthem Biosciences?

Shares Rs. in
Crore
QIB (50 %)  29708300 1693.38
NII (15 %)    8912500   508.01
RII (35 %)  20795800 1185.36
Employees    158650       8.25
Total Shares  59561403 3395.00
Retail portion will be oversubscribed by   Forms.
How to apply in Anthem Biosciences IPO? Amount
Rs.
Min Retail Application   26   Shares     14820
Max Retail Application   338  Shares   192660
Small HNI (Min)   364  Shares   207480
Small HNI (Max)  1742 Shares   992940
Big HNI Application  1768 Shares 1007760

What is the timetable of Anthem Biosciences IPO?

IPO opens on 14 July 2025
IPO Closes on 16 July 2025
IPO Allotment on  17 July 2025
Unblocking of ASBA  18 July 2025
Credit of Shares 18 July 2025
Listing on 21 July 2025
Registered Office of Anthem Biosciences
Anthem Biosciences Limited
No. 49, F1 & F2, Canara Bank Road
Bommasandra Industrial Area, Phase 1,
Bommasandra,
Bengaluru, Karnataka, 560099
The Lead Managers of the IPO
Jm Financial Limited 

Citigroup Global Markets India Pvt Ltd
J.P. Morgan India Pvt Ltd
Nomura Financial Advisory And Securities (India) Pvt Ltd

Registrar to IPO
Kfin Technologies Limited

Anthem Biosciences Financials

Period Ended 31-Mar-25 31-Mar-24 31-Mar-23
Assets 2,807.58 2,398.11 2,014.46
Revenue 1,930.29 1,483.07 1,133.99
Profit After Tax 451.26 367.31 385.19
EBITDA 683.78 519.96 446.05
Net Worth 2,409.86 1,924.66 1,740.67
Reserves and Surplus 2,298.05 1,815.39 1,628.88
Total Borrowing 108.95 232.53 125.06
Amount in Rs. Crore

Anthem Bioscience
Key Performance Indicators

KPI Values
ROE 20.82%
ROCE 26.88%
Debt/Equity 0.05
RoNW 20.82%
PAT Margin 23.38%
EBITDA Margin 36.81%
EPS 8.07
PE Ratio 70.63

How Anthem Biosciences IPO compares with the Peers?

Company Name P/E (x) RoNW (%)
Anthem Biosciences Limited 70.63 20.82
Syngene International Ltd 51.54 11.05
Sai Life Sciences Limited 92.18 10.96
Cohance Lifesciences Limited 97.29 13.61
DIVI’S LABORATORIES Limited 83.22 15.35

# This is only coverage of News related to Grey Market. We do not deal in grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.

Anthem Biosciences IPO Review

Anthem Biosciences Limited – IPO Review

Established in 2006, Anthem Biosciences Limited is a leading innovation-driven Contract Research, Development & Manufacturing Organization (CRDMO). With end-to-end capabilities in drug discovery, development, and commercial manufacturing, the company partners with cutting-edge biotech startups and global pharmaceutical giants.

Its expertise lies in fermentation-based APIs such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars—catering to high-growth healthcare markets worldwide.

🌍 Global Presence & Clientele

  • Operations in 44+ countries, including the U.S., Europe, and Japan

  • Serves over 550 clients across its CRDMO and specialty ingredients businesses

  • Revenue Contribution: 26.42% from North America, 54.61% from Europe

📈 Financial Strength & Growth

  • Consistent topline and bottom-line growth over the past 3 years

  • Declining attrition rates, particularly in R&D, show internal stability

  • Very low debt-equity ratio; the company is on track to be debt-free this year

Though the IPO is priced at a slightly higher valuation, it still offers room for listing gains and long-term appreciation.

Chanakya Recommendation: Apply

Quicklinks

Anthem Biosciences IPO GMP

Anthem Biosciences IPO GMP today details



Anthem Biosciences IPO GMP grey market premium, review, Subscription, allotment, listing estimate

Leave a Reply

Your email address will not be published. Required fields are marked *